Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor

被引:327
作者
Cani, PD
Knauf, C
Iglesias, MA
Drucker, DJ
Delzenne, NM
Burcelin, R
机构
[1] Univ Toulouse 3, CNRS, UMR, F-31062 Toulouse, France
[2] Catholic Univ Louvain, Unit Pharmacokinet Metab Nutr & Toxicol, B-1200 Brussels, Belgium
[3] Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Toronto, ON M5G 1L7, Canada
关键词
D O I
10.2337/db05-1360
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nondigestible fermentable dietary fibers such as oligofructose (OFS) exert an antidiabetic effect and increase the secretion of glucagon-like peptide 1 (GLP-1). To determine the importance of GLP-1 receptor-dependent mechanisms for the actions of OFS, we studied high-fat-fed diabetic mice treated with OFS for 4 weeks in the presence or absence of the GLP-1 receptor antagonist exendin 9-39 (Ex-9). OFS improved glucose tolerance, fasting blood glucose, glucose-stimulated insulin secretion, and insulin-sensitive hepatic glucose production and reduced body weight gain. Ex-9 totally prevented the beneficial effects of OFS. Furthermore, GLP-1 receptor knockout mice (GLP-1R(-/-)) were completely insensitive to the antidiabetic actions of OFS. At the molecular level, the effects of OFS on endogenous glucose production correlated with changes of hepatic IRS (insulin receptor substrate)-2 and Akt phosphorylation in an Ex-9-dependent manner. As inflammation is associated with diabetes and obesity, we quantified nuclear factor-kappa B and inhibitor of kappa B kinase beta in the liver. The activity of both intracellular inflammatory effectors was reduced by OFS but, importantly, this effect could not be reverted by Ex-9. In summary, our data show that the antidiabetic actions of OFS require a functional GLP-1 receptor. These findings highlight the therapeutic potential of enhancing endogenous GLP-1 secretion for the treatment of type 2 diabetes.
引用
收藏
页码:1484 / 1490
页数:7
相关论文
共 44 条
[1]   Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice [J].
Ahrén, B .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2004, 286 (02) :R269-R272
[2]   IKK-β links inflammation to obesity-induced insulin resistance [J].
Arkan, MC ;
Hevener, AL ;
Greten, FR ;
Maeda, S ;
Li, ZW ;
Long, JM ;
Wynshaw-Boris, A ;
Poli, G ;
Olefsky, J ;
Karin, M .
NATURE MEDICINE, 2005, 11 (02) :191-198
[3]   Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms [J].
Balkan, B ;
Li, X .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2000, 279 (04) :R1449-R1454
[4]   Free fatty acids in obesity and type 2 diabetes:: defining their role in the development of insulin resistance and β-cell dysfunction [J].
Boden, G ;
Shulman, GI .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 :14-23
[5]  
BONNER G, 1994, J CARDIOVASC PHARM, V24, pS39
[6]   Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet [J].
Burcelin, M ;
Crivelli, V ;
Dacosta, A ;
Roy-Tirelli, A ;
Thorens, B .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2002, 282 (04) :E834-E842
[7]   The incretins: a link between nutrients and well-being [J].
Burcelin, R .
BRITISH JOURNAL OF NUTRITION, 2005, 93 :S147-S156
[8]   Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor [J].
Burcelin, R ;
Da Costa, A ;
Drucker, D ;
Thorens, B .
DIABETES, 2001, 50 (08) :1720-1728
[9]   Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB [J].
Cai, DS ;
Yuan, MS ;
Frantz, DF ;
Melendez, PA ;
Hansen, L ;
Lee, J ;
Shoelson, SE .
NATURE MEDICINE, 2005, 11 (02) :183-190
[10]   Involvement of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats [J].
Cani, PD ;
Daubioul, CA ;
Reusens, B ;
Remacle, C ;
Catillon, G ;
Delzenne, NM .
JOURNAL OF ENDOCRINOLOGY, 2005, 185 (03) :457-465